SAN DIEGO, Oct. 20 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) announced today that research studies have documented the Aethlon Hemopurifier® is effective in capturing the current pandemic strain of the H1N1 Swine Flu Virus. The Hemopurifier® is the first-in-class medical device able to selectively remove infectious viruses and immunosuppressive proteins from the bloodstream. During invitro studies, the Hemopurifier® removed 68% of H1N1 virus from blood plasma in 30 minutes, 80% of the virus in two hours, and a 96% reduction of H1N1 was observed at six hours. The studies were performed by third party researchers approved by the United States Department of Health and Human Services (HHS) to house and conduct research on the current pandemic strains of H1N1 virus.
"The confirmation of the same Hemopurifier® we are advancing in Hepatitis-C (HCV) care, having significant activity against H1N1 virus is quite timely when considering the evolving rate of the pandemic," stated Aethlon Chairman & CEO, Jim Joyce. At present, the 2009 H1N1 influenza virus is the predominant influenza virus in circulation in most countries worldwide. Additional information on the virus, including situational updates can be accessed online at http://www.cdc.gov/H1N1flu.
Previous studies of the Hemopurifier® also demonstrated the ability of the device to capture both the reconstructed Spanish flu of 1918 virus (1918rv) and the H5N1 avian influenza virus (Bird Flu). As an adjunct therapy, the Hemopurifier® offers to improve the benefit of antiviral drugs against highly virulent strains of influenza and provides a therapeutic option against emerging strains of influenza that are resistant to drug and vaccine therapies.
About Aethlon Medical
Aethlon Medical creates diagnostic and therapeutic device solutions for infectious disease and cancer. Our Hemopurifier® represents the first-in-class medical device to selectively adsorb viruses and immunosuppressive toxins from the bloodstream. The Hemopurifier® seeks to improve Hepatitis-C treatment outcomes and serves as a broad-spectrum treatment countermeasure against bioterror and pandemic threats. Additional information regarding Aethlon Medical can be accessed online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the capability of the Hemopurifier® to reduce viral loads and other disease conditions, including H1N1 influenza, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts: RedChip Companies, Inc. Jon Cunningham 1-800-733-2447, Ext. 107 Jon@redchip.com Jim Joyce Chairman, CEO 858.459.7800 x301 firstname.lastname@example.org Jim Frakes Senior VP Finance 858.459.7800 x300 email@example.com
SOURCE Aethlon Medical, Inc.
|SOURCE Aethlon Medical, Inc.|
Copyright©2009 PR Newswire.
All rights reserved